ESTIMATED
04/17/2024
04/17/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 11 | $0.96 | $0.96 | $0.96 |
Q2 2024 | 14 | $1.10 | $1.13 | $1.11 |
Q3 2024 | 9 | $1.21 | $1.21 | $1.21 |
Q4 2024 | 6 | $1.33 | $1.33 | $1.33 |
Q1 2025 | 7 | $1.13 | $1.13 | $1.13 |
Q2 2025 | 8 | $1.27 | $1.27 | $1.27 |
Q3 2025 | 7 | $1.33 | $1.33 | $1.33 |
Q4 2025 | 7 | $1.44 | $1.44 | $1.44 |
Q1 2026 | 6 | $1.28 | $1.28 | $1.28 |
Q2 2026 | 11 | $1.44 | $1.44 | $1.44 |
Q3 2026 | 6 | $1.50 | $1.50 | $1.50 |
Q4 2026 | 9 | $1.63 | $1.63 | $1.63 |
Abbott Laboratories last posted its earnings results on Wednesday, April 17th, 2024. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.955 by $0.025. The company had revenue of 9.96 B for the quarter and had revenue of 40.11 B for the year. Abbott Laboratories has generated $3 earnings per share over the last year ($3.26 diluted earnings per share) and currently has a price-to-earnings ratio of 31.48. Abbott Laboratories has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, July 18th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/02/2024 | Q1 2024 | $0.71 | $9.88 B | $9.96 B | 02/16/2024 | Q4 2023 | $0.92 | $10.19 B | $10.24 B | 11/01/2023 | Q3 2023 | $0.83 | $10.14 B | 08/03/2023 | Q2 2023 | $0.79 | $9.98 B | 05/04/2023 | Q1 2023 | $0.76 | $9.67 B | $9.75 B | 02/17/2023 | Q4 2022 | $0.59 | $9.66 B | $10.09 B | 11/01/2022 | Q3 2022 | $0.82 | $10.41 B | 08/02/2022 | Q2 2022 | $1.15 | $11.26 B | 05/03/2022 | Q1 2022 | $1.40 | $11.90 B | 02/18/2022 | Q4 2021 | $1.13 | $10.71 B | $11.47 B | 11/03/2021 | Q3 2021 | $1.19 | $9.56 B | $10.93 B | 08/04/2021 | Q2 2021 | $0.67 | $9.69 B | $10.22 B | 05/05/2021 | Q1 2021 | $1.01 | $10.46 B | 02/19/2021 | Q4 2020 | $1.22 | $9.94 B | $10.70 B | 11/04/2020 | Q3 2020 | $0.70 | $8.54 B | $8.85 B | 07/29/2020 | Q2 2020 | $0.30 | $6.81 B | $7.33 B | 04/29/2020 | Q1 2020 | $0.32 | $7.73 B | 02/21/2020 | Q4 2019 | $0.60 | $8.27 B | $8.31 B | 10/31/2019 | Q3 2019 | $0.54 | $8.11 B | $8.08 B | 07/31/2019 | Q2 2019 | $0.57 | $8.00 B | $7.98 B |
---|
A. Abbott Laboratories has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, July 18th, 2024 based off last year's report dates.
A. In the previous quarter, Abbott Laboratories (NYSE:ABT) reported $0.98 earnings per share (EPS) to beat the analysts' consensus estimate of $0.955 by $0.025.
A. The conference call for Abbott Laboratories's latest earnings report can be listened to online.
A. The conference call transcript for Abbott Laboratories's latest earnings report can be read online.
A. Abbott Laboratories (NYSE:ABT) has a recorded annual revenue of $40.11 B.
A. Abbott Laboratories (NYSE:ABT) has a recorded net income of $40.11 B. Abbott Laboratories has generated $3.3 earnings per share over the last four quarters.
A. Abbott Laboratories (NYSE:ABT) has a price-to-earnings ratio of 31.48 and price/earnings-to-growth ratio is 4.81.